Haleon plc (NYSE:HLN) Holdings Lowered by Hsbc Holdings PLC

Hsbc Holdings PLC trimmed its stake in shares of Haleon plc (NYSE:HLN) by 33.0% in the 4th quarter, HoldingsChannel reports. The firm owned 10,167 shares of the company’s stock after selling 5,008 shares during the quarter. Hsbc Holdings PLC’s holdings in Haleon were worth $97,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Stifel Financial Corp lifted its holdings in shares of Haleon by 4.6% during the fourth quarter. Stifel Financial Corp now owns 2,033,298 shares of the company’s stock valued at $19,398,000 after purchasing an additional 88,749 shares during the last quarter. First Trust Advisors LP acquired a new position in Haleon during the fourth quarter valued at $517,000. Forum Financial Management LP raised its position in Haleon by 52.2% during the fourth quarter. Forum Financial Management LP now owns 30,705 shares of the company’s stock valued at $293,000 after buying an additional 10,530 shares during the period. GeoWealth Management LLC raised its position in Haleon by 67.4% during the fourth quarter. GeoWealth Management LLC now owns 9,876 shares of the company’s stock valued at $94,000 after buying an additional 3,975 shares during the period. Finally, NewEdge Advisors LLC raised its position in Haleon by 80.4% during the fourth quarter. NewEdge Advisors LLC now owns 60,949 shares of the company’s stock valued at $581,000 after buying an additional 27,163 shares during the period. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Stock Performance

Shares of HLN stock opened at $10.71 on Tuesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. Haleon plc has a fifty-two week low of $8.24 and a fifty-two week high of $10.85. The stock’s 50-day moving average is $10.21 and its two-hundred day moving average is $9.84. The firm has a market cap of $48.28 billion, a P/E ratio of 31.49, a PEG ratio of 2.82 and a beta of 0.24.

Haleon (NYSE:HLN) last issued its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The company had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.38 billion. Analysts predict that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The company also recently announced a — dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be given a $0.1166 dividend. This is a positive change from Haleon’s previous — dividend of $0.05. This represents a yield of 1.6%. The ex-dividend date is Friday, April 25th. Haleon’s dividend payout ratio is presently 58.97%.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on HLN. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Haleon in a research report on Monday, March 3rd. Morgan Stanley raised Haleon from an “equal weight” rating to an “overweight” rating and set a $11.25 price target on the stock in a research report on Friday. Hsbc Global Res lowered Haleon from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Barclays reissued an “overweight” rating on shares of Haleon in a research report on Tuesday, May 6th. Finally, HSBC reissued a “hold” rating on shares of Haleon in a research report on Wednesday, March 5th. Five equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $11.25.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.